|
Vogelstein B, Kinzler K W. Has the breast cancer gene been found [J]. Cell, 1994(1):1.
|
|
Miki Y, Swensen J, Shattuck-Eidens D. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 [J]. Science, 1994, (5182):66.
|
|
Wilson C A, Ramos L, Villasenor M R. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas [J]. Nature Genetics, 1999(2):236.
|
|
Horiuchi A, Wang C, Kikuchi N. BRCA1 Expression is an Important Biomarker for Chemosensitivity:Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells [J]. Biomark Insights, 2007.49.
|
|
Gilmore P M, McCabe N, Quinn J E. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3 [J]. Cancer Research, 2004, (12):4148.
|
|
Tassone P, Tagliaferri P, Perricelli A. BRCA1 expres sion modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells [J]. British Journal of Cancer, 2003(8):1285.
|
|
Lafarge S, Sylvain V, Ferrara M. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway [J]. Oncogene, 2001, (45):6597.
|
|
Promkan M, Liu G, Patmasiriwat P. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells [J]. International Journal of Cancer, 2009, (12):2820.
|
|
Saiki Y, Ogawa T, Shiga K. A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane [J]. Int J Otolaryngol, 2011.521852.
|
|
ZhouC, SmithJ L, LiuJ. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 [J]. Oncogene, 2003, (16):2396.
|
|
Kang C H, Jang B G, Kim D W. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaⅢ-tubulin expression in patients with non-small cell lung cancer treated by platinum-and taxane-based neoadjuvant chemotherapy and surgical resection [J]. Lung Cancer, 2010(3):478.
|
|
Boukovinas I, Papadaki C, Mendez P. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-smallcell lung cancer patients [J]. PLOS One, 2008, (11):3695.
|
|
Rosell R, Perez-Roca L, Sanchez J J. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression [J]. PLOS One, 2009(5):5133.
|
|
Papadaki C, Tsaroucha E, Kaklamanis L. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer [J]. British Journal of Cancer, 2011(2):316.
|
|
Chabalier C, Lamare C, Racca C. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance [J]. Cell Cycle, 2006(9):1001.
|
|
Byrski T, Gronwald J, Huzarski T. Response to neoadjuvant chemotherapy in women with BRCA1-positive breast cancers [J]. Breast Cancer Research and Treatment, 2008(2):289.
|
|
Wysocki Pj, Korski K, Lamperska K. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations [J]. Medical Science Monitor, 2008(7):7.
|
|
Kriege M, Jager A, Hooning M J. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers [J]. Cancer, 2012(4):899.
|
|
Gallagher D J, Cronin A M, Milowsky M I. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer [J]. British Journal of Urology International, 2012(5):713.
|
|
Reding K W, Bemstein J L, Langholz B M. Adjuvant systemic therapy for breast cancer in BRCA1 /BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer [J]. Breast Cancer Research and Treatment, 2010(2):491.
|
|
Trenz K, Lugowski S, Jahrsdorfer U. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics [J]. Mutation Research, 2003, (2-3):279.
|
百度学术
下载:
苏公网安备 32100302010246号
